48
Participants
Start Date
January 31, 2015
Primary Completion Date
March 17, 2025
Study Completion Date
March 17, 2025
18F-MFBG (meta-fluoro benzylguanidine)
About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
Positron emission tomography (PET) imaging
Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
Blood draws
Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center
OTHER